The Anti-Aging Peptide That Works On 900 Longevity Genes (GHK-Copper Explained) | Kyal Van Der Leest
Why It Matters
Effective oral delivery of GHK‑Cu could democratize a potent longevity peptide, driving new product categories in nutraceuticals and skincare and offering measurable anti‑aging benefits.
Key Takeaways
- •Oral GHK can survive stomach acid, achieving systemic effects
- •Liposomal GHK improves bioavailability, targeting skin and cardiovascular health
- •Non‑liposomal GHK acts locally in gut, repairing intestinal lining
- •GHK modulates ~900 longevity genes, boosting stem cell activation
- •Combining GHK with hyaluronic acid synergistically enhances skin hydration and collagen
Summary
The video explains how the tripeptide GHK‑copper (GHK‑Cu) can be used as an oral and topical anti‑aging ingredient, highlighting its ability to survive stomach acid and reach systemic circulation.
Because GHK is only three amino acids, it can cross the intestinal epithelium; liposomal encapsulation raises systemic bioavailability from roughly 15 % to a therapeutically relevant level, while the non‑liposomal form remains in the gut lumen to repair the intestinal lining. The peptide is reported to favorably regulate about 900 longevity‑related genes, stimulate stem‑cell proliferation, and boost collagen and elastin synthesis.
The presenter cites the Picket and Vasquez study that documents GHK’s epigenetic activation of anti‑oxidative pathways, and notes that pairing GHK with high‑molecular‑weight hyaluronic acid creates a “magic combination” for skin hydration and extracellular‑matrix support. He also draws a parallel between gut health and skin health, describing the gut as an “internal skin” that benefits from the same collagen‑enhancing mechanisms.
If these delivery claims hold, GHK‑Cu could become a cornerstone of next‑generation nutraceuticals and cosmeceuticals, offering a scientifically backed route to improve skin, joint, and cardiovascular health while tapping into the growing longevity market.
Comments
Want to join the conversation?
Loading comments...